These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37380634)

  • 21. Delamanid: first global approval.
    Ryan NJ; Lo JH
    Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretomanid for the treatment of pulmonary tuberculosis.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Oct; 56(10):655-668. PubMed ID: 33185630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretomanid development and its clinical roles in treating tuberculosis.
    Fekadu G; Tolossa T; Turi E; Bekele F; Fetensa G
    J Glob Antimicrob Resist; 2022 Dec; 31():175-184. PubMed ID: 36087906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
    Manina G; Pasca MR; Buroni S; De Rossi E; Riccardi G
    Curr Med Chem; 2010; 17(27):3099-108. PubMed ID: 20629622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
    Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
    Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
    Thompson AM; Blaser A; Palmer BD; Anderson RF; Shinde SS; Launay D; Chatelain E; Maes L; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2583-2589. PubMed ID: 28462832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824).
    Baptista R; Fazakerley DM; Beckmann M; Baillie L; Mur LAJ
    Sci Rep; 2018 Mar; 8(1):5084. PubMed ID: 29572459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
    Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
    Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
    Gómez-González PJ; Perdigao J; Gomes P; Puyen ZM; Santos-Lazaro D; Napier G; Hibberd ML; Viveiros M; Portugal I; Campino S; Phelan JE; Clark TG
    Sci Rep; 2021 Sep; 11(1):19431. PubMed ID: 34593898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial Activity of 5-membered Nitroheteroaromatic Compounds beyond Nitrofurans and Nitroimidazoles: Recent Progress.
    Kalinin S; Vedekhina T; Paramonova P; Krasavin M
    Curr Med Chem; 2021; 28(29):5926-5982. PubMed ID: 33593249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alkylated/aminated nitroimidazoles and nitroimidazole-7-chloroquinoline conjugates: Synthesis and anti-mycobacterial evaluation.
    Shalini ; Viljoen A; Kremer L; Kumar V
    Bioorg Med Chem Lett; 2018 May; 28(8):1309-1312. PubMed ID: 29551480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
    Adeniji AA; Knoll KE; Loots DT
    Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria.
    Zhuang Z; Wan D; Ding J; He S; Zhang Q; Wang X; Yuan Y; Lu Y; Ding CZ; Lynch AS; Upton AM; Cooper CB; Denny WA; Ma Z
    Molecules; 2020 May; 25(10):. PubMed ID: 32456032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring Targets of Cell Wall Protein Synthesis and Overexpression Mediated Drug Resistance for the Discovery of Potential M. tb Inhibitors.
    Nandi S; Saxena AK
    Curr Top Med Chem; 2021; 21(21):1922-1942. PubMed ID: 34315374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretomanid: The latest USFDA-approved anti-tuberculosis drug.
    Deb U; Biswas S
    Indian J Tuberc; 2021 Apr; 68(2):287-291. PubMed ID: 33845969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.